We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
21
2 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
1947
Completed
10
47.6%
Not yet recruiting
2
9.5%
Recruiting
7
33.3%
Unknown
No approval data available
- Hyundai Bioscience's oral antiviral CP-COV03 (Xafty) demonstrated efficacy in treating COVID-19 symptoms in a randomized, double-blind, placebo-controlled trial with 300 patients. - The niclosamide-based drug showed faster recovery times and reduced hospitalization risk compared to placebo, with no serious adverse events reported. - CP-COV03 is positioned as a safer and more effective alternative to existing COVID-19 treatments like Paxlovid, with potential for broader antiviral applications. - The company plans to advance to later-stage trials and seek regulatory approval, with potential market availability next year if successful.
